Brana, Irene <br/><br/>
Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study.  [electronic resource] 

 -  Targeted oncology  Mar 2015 
 - 111-23 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1776-260X 
<br/><br/><label>Standard No.: </label>10.1007/s11523-014-0320-2  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Humanized<br/>Antibodies, Neutralizing--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Broadly Neutralizing Antibodies<br/>Carboplatin--administration & dosage<br/>Deoxycytidine--administration & dosage<br/>Docetaxel<br/>Doxorubicin--administration & dosage<br/>Female<br/>Humans<br/>Male<br/>Middle Aged<br/>Neoplasms--drug therapy<br/>Paclitaxel--administration & dosage<br/>Polyethylene Glycols--administration & dosage<br/>Taxoids--administration & dosage<br/>Gemcitabine